Regulatory Context According to MEDVi's published disclaimers: "The telehealth weight loss and prescription compounding industries have been under increased regulatory scrutiny in recent years." The FDA continues issuing guidance on compounding practices
Overall, GLP-1 RAs appear promising as adjunctive therapies for HS and psoriasis, especially in patients with coexisting metabolic disease
Anecdotal patient reports present a mixed picture
Because of the effects GLP-1 RAs have on digestion and appetite signals, GLP-1 users may eat less, drink less, and absorb less, explains Kwadwo Kyeremanteng, MDOpens in a new tab, department head of critical care at The Ottawa Hospital and LMNT Partner
The trial product estimand evaluated the treatment effect while on treatment and without the use of rescue medication [60], providing a more direct evaluation of medication efficacy